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Abstract 20 
β-Lactamase production increasingly threatens the effectiveness of β-lactams, which remain a 21 
mainstay of antimicrobial chemotherapy. New activities emerge both through mutation of 22 
previously known β-lactamases and mobilization from environmental reservoirs. The spread of 23 
metallo-β-lactamases (MBLs) represents a particular challenge through their typically broad 24 
spectrum activities, encompassing carbapenems in addition to other β-lactam classes. 25 
Increasingly, genomic and metagenomic studies reveal distribution of putative MBLs in the 26 
environment, but in most cases their activity against clinically relevant β-lactams, and hence the 27 
extent to which they can be considered a resistance reservoir, remains uncharacterized. Here we 28 
characterize the product of one such gene, blaRm3, identified through functional metagenomic 29 
sampling of an environment with high biocide exposure. blaRm3 encodes a subclass B3 MBL that, 30 
when expressed in recombinant E. coli, is exported to the bacterial periplasm and hydrolyzes 31 
clinically used penicillins, cephalosporins, and carbapenems with an efficiency limited by high 32 
KM values. An Rm3 crystal structure reveals the MBL superfamily αβ/βα fold, which more 33 
closely resembles mobilized B3 MBLs (AIM-1, SMB-1) than other chromosomal enzymes (L1 34 
or FEZ-1). A binuclear zinc site sits in a deep channel that is in part defined by a relatively 35 
extended N-terminus. Structural comparisons suggest that the steric constraints imposed by the 36 
N-terminus may limit β-lactam affinity. Sequence comparisons identify Rm3-like MBLs in 37 
numerous other environmental samples and species. Our data suggest that Rm3 like enzymes 38 
represent a distinct group of B3 MBLs with a wide distribution and can be considered as an 39 
environmental reservoir of β-lactam resistance.  40 
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Introduction 41 
The continued efficacy of β-lactam antibiotics is threatened by the dissemination of β-42 
lactamases, hydrolytic enzymes that inactivate these important drugs by cleavage of the scissile 43 
β-lactam amide bond (1). In the 70 years since β-lactams were first introduced to the clinic, 44 
repeated mobilizations of β-lactamase genes from a variety of bacterial sources have led to their 45 
rapid propagation in opportunistic Gram-negative pathogens such as the Enterobacteriaceae and 46 
non-fermenting species including Pseudomonas aeruginosa and Acinetobacter baumannii (2). 47 
Notably, some of the most successful β-lactamases, in particular the CTX-M extended-spectrum 48 
β-lactamase (ESBL) associated with resistance to third-generation cephalosporins such as 49 
cefotaxime, and which is now distributed worldwide (3), find their origins in environmental 50 
organisms, illustrating how transfer of antibiotic resistance genes from environmental to 51 
pathogenic species can have profound clinical consequences (4). In the case of CTX-M enzymes 52 
it is now accepted that these originated in Kluyvera spp. (5, 6), a Gram-negative rod bacterium 53 
that is found in both the human intestinal microbiome and the wider natural environment (7). 54 
β-Lactamases are divided, primarily on the basis of amino acid sequence, into four main classes 55 
(8). Of these, three (classes A, C and D) are active site nucleophilic serine enzymes (SBLs) and 56 
the remaining class, B, zinc metalloenzymes that are structurally and mechanistically unrelated 57 
to the SBLs. The metallo-β-lactamases (MBLs) are themselves divided into a further three 58 
groups (B1, B2 and B3) on the basis of sequence differences that are manifest as variations in the 59 
number (1 or 2) of zinc ions required for full activity, and in structural differences that include 60 
variations in co-ordination of the active site zinc ions (9, 10). MBLs are a growing clinical 61 
concern as they effectively hydrolyze all β-lactam classes excepting the monobactams and 62 
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escape the action of SBL inhibitors (11) that are at (clavulanate, tazobactam) or close to 63 
(avibactam, relebactam) the clinic. B1 MBLs such as the NDM (12) and VIM (13) enzymes are 64 
now encountered with increasing frequency on mobile genetic elements in organisms such as 65 
Escherichia coli, Klebsiella pneumoniae, P. aeruginosa and A. baumannii. 66 
While B3 family members such as AIM-1 (14) and SMB-1 (15) have been identified on mobile 67 
genetic elements, the majority of these enzymes are chromosomal. However, in addition to their 68 
presence in opportunist pathogens such as Stenotrophomonas maltophilia (16) and 69 
Elizabethkingia meningosepticum (17), the B3 MBLs also have a very wide distribution in 70 
environmental organisms and sequences. Compared to the B1 enzymes, the B3 MBLs are less 71 
well studied, display a greater degree of structural and sequence diversity and are more closely 72 
related to other branches of the wider metallo-hydrolase superfamily to which the MBLs belong 73 
(18). Investigations of B3 MBLs from environmental sources will thus expand our understanding 74 
of activity and structure within this group of enzymes and provide insights into the nature and 75 
extent to which MBLs in the environment provide a reservoir of resistance determinants to the 76 
most clinically important β-lactam antibiotics. Furthermore, identifying how the distribution of 77 
such sequences changes in response to human activity (i.e. exposure to antimicrobials within the 78 
environment) can also provide evidence of the effect of human activity upon the environmental 79 
resistance reservoir (19). 80 
Technological advances have transformed our ability to sample and identify antibiotic resistance 81 
genes in the natural environment. In particular, combining sequence-based (metagenomics) with 82 
functional (construction and analysis of large libraries) methodologies can both establish the 83 
prevalence and distribution of putative resistance genes and identify those that confer a 84 
resistance phenotype, i.e that are able to alter antibiotic susceptibility in a model organism (e.g. 85 
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E. coli) (20-22). This study provides a biochemical and structural characterization of a B3 MBL, 86 
Rm3, that was identified by application of this functional metagenomics approach to study the 87 
distribution of resistance to third-generation cephalosporins in environmental sources selected on 88 
the basis of differing degrees of human impact. (Full details of the identification of Rm3 will be 89 
presented elsewhere). The blaRm3 gene (GenBank accession KF485393.2) was isolated from a 90 
metagenomic library derived from soil from a reed bed used to bioremediate effluent from a 91 
textile mill with high usage of quaternary ammonium compounds (QACs). Screening of this 92 
library identified blaRm3 as one of a number of novel β-lactamase genes able to decrease 93 
susceptibility of recombinant E. coli to third generation cephalosporins. 94 
The Rm3 amino acid sequence (Figure 1) most closely resembles other putative B3 MBLs from 95 
environmental bacteria, in particular sequences from the soil bacteria Janthinobacterium (e.g. 96 
GenBank KKO63914.1; 89 % sequence identity (23)) and Solimonas (e.g. NCBI accession 97 
WP_020650668.1; 56 % identity) spp. Rm3 also resembles (54 % sequence identity) a novel B3 98 
MBL, LRA-8, identified from a metagenomics study of the Tanana river in Central Alaska (20) 99 
(Figure 1), and a related sequence (GenBank AIA12579.1; 56 % identity) identified from a 100 
grassland soil sample from Minnesota, U.S.A., as part of a functional metagenomics study of 101 
environmental antibiotic resistance genes (24). Of biochemically characterized B3 MBLs, Rm3 102 
shares the highest sequence identity with THIN-B (25) (49%) and is between 43% (SMB-1) (15) 103 
and 27% (BJP-1) (26) identical to enzymes of known structure. On this basis, (Figures 1,2), Rm3 104 
can be considered as being representative of a group of uncharacterized novel B3 MBLs that 105 
appear to be widely distributed within the environmental microbiome. Here we present the 106 
biochemical and structural characterization of recombinant Rm3. 107 
  108 
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Materials and Methods 109 
Identification of blaRm3 110 
Full details of the identification of Rm3 will be presented elsewhere. Briefly, core samples were 111 
obtained from reed beds used for remediation of effluent from a textile mill in Yorkshire, U.K., 112 
(27) and total DNA was purified as previously described (21). A metagenomic library was 113 
generated by cloning purified DNA fragments into plasmid pCF430 (28) and transforming into 114 
E. coli strain EC100 (Epicentre, Madison WI, U.S.A.) by electroporation. Recombinants were 115 
passaged over 10-20 generations and clones resistant to third generation cephalosporins selected 116 
by plating on ceftazidime (1 μg / ml). Putative resistance genes were identified by sequencing 117 
positive clones, and their contribution to the resistance phenotype confirmed by inactivation 118 
using transposon mutagenesis (EZ-Tn5 kit, Epicentre) allowing for selection by loss of 119 
phenotype (21). 120 
 121 
Minimal Inhibitory Concentration (MIC) Determination for Metagenomic Clones 122 
Minimal inhibitory concentration (MIC) values for metagenomic clones were determined by agar 123 
dilution on Iso-sensi Test Agar (Oxoid) with an inoculum of 105 colony forming units (cfu) per 124 
spot (29). 125 
 126 
Recombinant Rm3 Expression and Purification 127 
The complete Rm3 open reading frame (including the putative periplasmic export sequence) was 128 
amplified from metagenomic clone RM3 by PCR with primers RM3F 129 
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(AAGGCATATGATGTCCCTCACACCACCACGCGCG) and RM3R2(AATGGGATCCTTAC 130 
TGCTGTTTTTCCTGGT) with proof-reading Pfu DNA polymerase. The product was ligated 131 
into the T7 expression vector pET26b (30) using the Nde1 and BamH1 restriction sites and the 132 
integrity of the resulting plasmid pLHZRM3 confirmed by DNA sequencing. E. coli 133 
ArcticExpress (DE3) competent cells (Agilent, Stockport, U.K.) transformed with pLHZRM3 134 
were grown (Power Broth (Athena Enzyme Systems, Baltimore, MD, U.S.A.); 30° C; 160 rpm 135 
shaking) to OD600nm ≈ 0.6 and expression induced overnight (1 mM isopropyl-β-D-136 
thiogalactopyranoside (Melford Laboratories, Ipswich, U.K.); 13° C). Cells were harvested by 137 
centrifugation (7 205 g; 30 mins; 4° C) and lysed in a Constant Systems (Daventry, U.K.) cell 138 
disruptor (25 000 psi). Debris was removed by centrifugation (38 724 g, 1 h) and the supernatant 139 
exchanged into buffer A (50 mM potassium phosphate pH 7.0, 1 M ammonium sulfate) by 140 
extensive dialysis using a 3 000 Da cut-off membrane (Medicell International, London, U.K.). 141 
Protein for crystallography was purified by the following method. 20 ml of the dialysate was 142 
loaded on a 1 ml Phenyl FF HS column (GE Healthcare Life Sciences, Little Chalfont, U.K.) and 143 
the column washed consecutively with buffer B (buffer A plus 10 mM MgCl2, 5 mM ATP, 50 144 
mM KCl) and buffer A prior to elution on a gradient of 0 – 50 % buffer C (50 mM potassium 145 
phosphate pH 7.0). Rm3-containing fractions were identified by SDS-PAGE (31) and 146 
concentrated to a volume of ~2 ml by centrifugal ultrafiltration using an Amicon concentrator 147 
with a 3 000 Da molecular weight cut off (Millipore, Watford, U.K.). Protein was loaded onto a 148 
300 ml Superdex S75 size exclusion column (GE Healthcare) and eluted with a flow rate of 1 ml 149 
/ min in buffer D (20 mM Tris pH 7.5, 200 mM NaCl). Rm3-containing fractions were pooled 150 
and concentrated as above. 151 
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For enzyme kinetic experiments Rm3 was purified by a modified version of the above protocol 152 
where recombinant protein was produced in E. coli SoluBL21 cells (AMS Biotechnology, 153 
Abingdon, U.K.) that were grown overnight in Autoinduction Terrific Broth (Formedium, 154 
Hunstanton, U.K.) at 25° C. The hydrophobic interaction chromatography step utilized a 40 ml 155 
Phenyl FF HS column, omitted the ATP wash and eluted bound protein on a 0 – 100 % buffer C 156 
gradient; and size exclusion chromatography utilized a 120 ml HiLoad 16/60 Superdex 75 pg 157 
column (GE Healthcare). 158 
 159 
Verification of Recombinant Rm3 by Mass Spectrometry 160 
ESI mass analyses were acquired (as described (32)) in the positive ion mode using a Waters 161 
(Elstree, U.K.) LCT Premier instrument equipped with a TOF analyzer. An LCT Premier mass 162 
spectrometer (Waters) was coupled to an Agilent 1100 Series HPLC using a Chromolith® 163 
FastGradient RP-18 endcapped column equipped with a 50‑2 HPLC column, made of 164 
monolithic silica (C18, 2 x 50 mm, macropores with 1.6 µm diameter, Merck (Beeston, U.K.)). 165 
The instrument was connected to a CTC‑autosampler inlet system. A multi‑step gradient over 166 
10 min was run (solvent A 94.9% H2O/5% CH3CN/0.1% formic acid, solvent B 99.9% 167 
CH3CN/0.1% formic acid; 0‑1 min 5% B for equilibration, followed by a linear gradient to 168 
100% B over 4 min, then 100% B for an additional 3 min, followed by a linear gradient over 2 169 
min back to 5% B to re‑equilibrate the column) to separate the protein samples at flow rates of 170 
0.4 ml / min for the first 5 min and then 1.0 ml / min for the remaining time. The electrospray 171 
ionization source used a capillary voltage of 3.2 kV and cone voltage of 25 V. Nitrogen was used 172 
as the nebulizer and desolvation gas at a flow rate of 600 l/h. Protein typically eluted as a peak 173 
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between 3 and 5 min under these conditions. Calculated masses were obtained using the ExPasy 174 
ProtParam tool (http://web.expasy.org/protparam/ (33)). 175 
 176 
Steady-State Kinetics of β-Lactam Hydrolysis by Recombinant Rm3 177 
Hydrolysis of selected β-lactams by recombinant Rm3 was investigated under steady-state 178 
conditions. The buffer was 50 mM HEPES, pH 7.0, supplemented with 100 µM ZnCl2 and 100 179 
µg/ml BSA and the protein concentration was 10 nM. Measurements used either a Polarstar 180 
Omega plate reader (BMG LabTech, Aylesbury, U.K.) or, for complete hydrolysis curves, a 181 
Lamda 35 spectrophotometer (Perkin-Elmer, Seer Green, U.K.). Extinction coefficients and 182 
wavelengths used (34) were: -775 M-1 cm-1 at 235 nm (penicillin G); -820 M-1 cm-1 at 235 nm 183 
(ampicillin); -7700 M-1 cm-1 at 260 nm (cefoxitin); -9000 M-1 cm-1 at 260 nm (ceftazidime); -184 
7500 M-1 cm-1-at 260 nm (cefotaxime); - 6500 M-1 cm-1 at 300 nm (meropenem); - 9000 M-1 cm-1 185 
at 300 nm (imipenem); and -700 M-1 cm-1 at 320 nm (aztreonam). 186 
Data were analyzed by fitting to the Michaelis-Menten equation: 187 
V = kcat*[E]*[S] / (KM + [S]) 188 
Where V is the measured initial velocity at substrate concentration [S] and [E] is the 189 
concentration of enzyme. Where high apparent KM values precluded data collection under the 190 
conditions required to achieve saturation of hydrolysis rate, the value of kcat/KM was measured by 191 
fitting progress curves (absorbance versus time) for a complete hydrolysis reaction to the 192 
exponential: 193 
At = A∞ + (A0 − A∞)*e−kt 194 
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where At is the absorbance at time t and A0 the initial and A∞ the final absorbance. The observed 195 
first-order rate constant is then k = ( kcat/KM )*[E] (35). Curve fitting was undertaken using Prism 196 
(GraphPad, La Jolla, CA, U.S.A.). 197 
 198 
Rm3 Crystallization and Structure Determination 199 
Purified Rm3 protein in buffer D was concentrated to ~13 mg / ml by ultracentrifugation as 200 
above and supplemented with 100 µM ZnCl2 and 5 mM Tris(2-carboxyethyl)phosphine (TCEP) 201 
hydrochloride (Fisher Scientific). Initial crystallization hits were obtained from commercial 202 
sparse matrix screening kits (Molecular Dimensions (Newmarket, U.K.) Proplex (36)) using a 203 
Phoenix crystallization robot (Art Robbins Instruments, Sunnyvale, CA, U.S.A.) to set 100 nl 204 
plus 100 nl sitting drops in 96-well MRC plates (Molecular Dimensions) using a reservoir 205 
volume of 100 µl. Conditions were optimized using 1 µl plus 1 µl hanging drops in 24-well XRL 206 
plates (Molecular Dimensions) with 500 µL reservoir volume. Diffraction data were collected 207 
from a single crystal grown in a hanging drop from 14% w/v PEG 8000, 0.1 M Tris pH 8, 0.15 208 
M LiCl. All crystallization experiments were carried out at 18 °C. 209 
The Rm3 crystal was cryoprotected for ~30 seconds by exposure to reservoir solution 210 
supplemented with 25% ethylene glycol, mounted in a SPINE standard pin (Molecular 211 
Dimensions) and flash frozen in liquid nitrogen. Diffraction data were collected on beamline I04 212 
of the Diamond Light Source (DLS), U.K., using a Pilatus 6M-F detector. 934 images of 0.15° 213 
oscillation (exposure 0.15 s per image; 20% beam intensity) were collected at a wavelength of 214 
0.9795 Å. Diffraction data were integrated using XDS (37), the space group was identified using 215 
Pointless (38) and data were scaled and merged using Aimless (38) as implemented in the Xia2 216 
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pipeline (39). The structure was solved by molecular replacement using Phaser (40) with 217 
Chainsaw (41) used to create a search model based upon S. maltophilia L1 (chain A of PDB 218 
2QDT (42)) by pruning side chains of non-identical amino acids to their Cγ atoms. Models were 219 
built in Coot (43) and refinement carried out using Refmac 5 (44). Final refinement and model 220 
validation (MolProbity (45)) took place in Phenix (46). 221 
Coordinates and structure factors have been deposited in the Protein Data Bank 222 
(www.rcsb.org/pdb) with accession no. 5IQK. 223 
  224 
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Results and Discussion 225 
Identification of Rm3 as a Subclass B3 Metallo-β-Lactamase 226 
blaRm3 was identified by selecting ceftazidime resistant clones from a metagenomic library 227 
constructed from DNA purified from samples originating from a reed bed used to bioremediate 228 
effluent from a textile mill with high usage of quaternary ammonium compounds (QACs). QACs 229 
are disinfective agents with wide industrial application, and have been implicated in the selection 230 
of co- and cross-resistance to a variety of antibiotic classes, including β-lactams (47, 48). blaRm3 231 
was situated on an 8 kb DNA fragment (metagenomic clone RM3; GenBank accession 232 
KF485393.2) that exerted variable effects upon susceptibility to β-lactam antibiotics but that 233 
resulted in a 16-fold elevation of the MIC of E. coli EC100 to CAZ (ceftazidime) compared to 234 
vector-only control (Table 1). This effect was abolished by insertional inactivation of blaRm3 by 235 
transposition (data not shown). The amino acid sequence of the blaRm3 encoded protein, Rm3, 236 
showed properties (presence of a His116-Xaa-His118-Xaa-Asp120-His121 sequence motif and 237 
similarity to previously characterized enzymes) characteristic of a subclass B3 MBL (Figure 1).  238 
 239 
Expression and Kinetic Characterization of Recombinant Rm3 240 
The blaRm3 gene encodes a 302 residue polypeptide that includes an N-terminal leader peptide of 241 
23 residues that was identified by SignalP (49) as a periplasmic export sequence. The complete 242 
Rm3 open reading frame, including the putative export sequence, was expressed in either E. coli 243 
ArcticExpress or SoluBL21 and was purified to apparent homogeneity by hydrophobic 244 
interaction and size exclusion chromatography. Quadrupole time-of-flight (QTOF) mass 245 
spectrometry under denaturing conditions gave a mass of 29 805 Da for the purified protein, 246 
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consistent with a predicted mass of 29 808.5 Da for the Rm3 fragment resulting from removal of 247 
the predicted precursor polypeptide after residue 23. Thus these data confirm that the leader 248 
peptide is removed from recombinant Rm3 by post-translational processing in E. coli, and 249 
strongly indicate that, as is the case for other β-lactamases of Gram-negative bacteria, the protein 250 
is exported to the bacterial periplasm. 251 
Steady-state kinetic experiments indicate that Rm3 is able to hydrolyze a range of penicillin, 252 
cephalosporin, and carbapenem antibiotics with varying degrees of efficiency (Table 2). Notably, 253 
it was possible to obtain accurate KM estimates for only two substrates, meropenem and 254 
ampicillin, of the eight that were evaluated. For the other substrates tested it proved difficult to 255 
saturate the Michaelis-Menten (i.e. rate versus substrate concentration) plots, indicating high KM 256 
values and likely low affinity. For these substrates, values for catalytic efficiency (kcat/KM) only 257 
are reported. Overall catalytic efficiencies approaching 105 M-1 s-1 are achieved for substrates 258 
from all classes excepting the monobactam aztreonam, against which Rm3, as is the case for 259 
other MBLs, shows no hydrolytic activity. These data show Rm3, in common with most other 260 
B3 MBLs, to be an enzyme with a broad spectrum of activity. The relatively low catalytic 261 
efficiencies that are achieved by Rm3, compared to other characterized B3 MBLs where values 262 
for kcat/KM in excess of 107 M-1 s-1 have been reported for some favorable enzyme:substrate 263 
combinations (e.g. AIM-1-catalyzed imipenem hydrolysis (14)), arise primarily from the 264 
relatively high  KM values. For all substrates tested KM values were 10 -4 M or above, contrasting 265 
with most other B3 MBLs where for more favored substrates KM values of 10 -5 M or better are 266 
obtained. Some other enzymes from environmental sources, such as J. lividum BJP-1 (26), 267 
Erwinia caratovora CAR-1 (50) and Caulobacter crescentus CAU-1 (51), are also notable for 268 
comparably high KM values across the range of β-lactams. However, Rm3 is distinguished from 269 
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many of these by an apparent lack of discrimination against oxyiminocephalosporins (e.g. 270 
ceftazidime) or 7-α-methoxy cephalosporins (e.g. cefoxitin) that are poor substrates for the B3 271 
enzymes CAR-1 and CAU-1, respectively. kcat/KM values for hydrolysis of these substrates by 272 
Rm3 are in line with those for other β-lactams tested. 273 
 274 
Crystal Structure of Rm3 275 
Rm3 crystallized in space group P21 with two molecules in the asymmetric unit. A single 1.75 Å 276 
resolution dataset was collected at the Diamond Light Source synchrotron radiation facility and 277 
phases and an initial electron density map calculated by molecular replacement. Data collection 278 
and refinement statistics are given in Table 3. The final structure contains 268 (chain A) and 269 279 
(chain B) residues, with electron density not observed for the 10 (chain A) or 9 (chain B) N-280 
terminal amino acids, or for the C-terminal glutamine residue of either polypeptide chain. We 281 
note that the N-terminus of processed Rm3 is formed by a proline-rich sequence (QTPAPATPP) 282 
that is likely to be unstructured in solution. 96.6 % of total residues are in the most favored 283 
regions of the Ramachandran plot, with no residues classed as outliers. The overall structure 284 
(Figure 3) is that of the MBL superfamily, comprising an αβ / βα fold in which the N- and C-285 
terminal halves of the protein form central seven- and five-stranded β-sheets, respectively, that 286 
are flanked by α-helices. The interface of these two sheets provides the location for the active 287 
site. The active site environment is defined by three loop regions that connect elements of 288 
secondary structure: residues 150 – 164 (loop 1) connecting helix α4 and strand β7; residues 192 289 
– 201 that connect strands β9 and β10 and residues 222 – 239 (loop 2) connecting strand β11 and 290 
helix α5. (The BBL numbering scheme (52) is used throughout this manuscript). 291 
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The presence of disulfide bonds also serves to define the overall architecture of the Rm3 292 
structure. The processed Rm3 polypeptide contains a total of 6 Cys residues, of which two 293 
(residues 256 and 290) form a disulfide bond between helices α5 and α7 that is common to all 294 
B3 MBLs of known structure excepting BJP-1 (53). In chain A of the current structure a second 295 
disulfide between Cys208 and Cys213 constrains the short loop between strands β10 and β11. 296 
However, in chain B this disulfide bond is not present, Cys208 and Cys213 are reduced and a 297 
zinc ion is positioned between them. This zinc ion is also coordinated by His246 and Glu249 of 298 
an adjacent chain and thus occupies a site that is formed at the interface of two Rm3 monomers 299 
in adjacent asymmetric units in the crystal. The final pair of Cys residues (positions 32 and 35) 300 
also contribute to a further zinc site at the interface between the two Rm3 molecules present in 301 
the crystallographic asymmetric unit, in which zinc co-ordination is completed by His158 of the 302 
opposing chain, and by a crystallographic water molecule. However, as Rm3 eluted from the size 303 
exclusion chromatography column at a volume consistent with a molecular weight of 304 
approximately 30 000 Da (data not shown), indicating that the protein is likely to exist as a 305 
monomer in solution, we consider both of these interface sites to be crystallization artefacts that 306 
are unlikely to exert a physiological function. 307 
Inspection of difference electron density maps from the early stages of refinement 308 
unambiguously identified the presence of two metal ions in the Rm3 active site. These were 309 
refined as zinc ions, based upon the presence of excess zinc in the crystallization experiment and 310 
the absence of other metal ions in the crystal as adjudged by the lack of additional peaks in an X-311 
ray fluorescence excitation spectrum collected at the synchrotron beamline (data not shown). 312 
Both sites were refined to 100 % occupancy with B-factors similar to those of the adjacent 313 
protein atoms (Table 3). Consistent with assignment of Rm3 as a member of the B3 MBL 314 
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subfamily, the two zinc ions respectively occupy the two binding sites that are defined by 315 
conserved residues of the MBL superfamily; i.e. a tri-histidine (Zn1) site formed by His116, 316 
His118 and His196 and an Asp – His – His (Zn2) site formed by Asp120, His121 and His263 317 
(Figure 4). In both subunits the two zinc ions lie approximately 3.5 Å apart (distances 3.46 Å and 318 
3.51 Å in chains A and B, respectively) and are connected by a “bridging” water molecule 319 
(Wat1, likely to exist as an hydroxide ion (54)) that is positioned asymmetrically with respect to 320 
the two metal ions and lies closer to Zn1 (1.81 - 1.90 Å) than to Zn2 (2.04 - 2.11 Å). Metal co-321 
ordination is completed by a second water molecule (Wat2) that lies closer to Zn2 but also co-322 
ordinates Zn1 (Wat2 – Zn1 distances 2.57 and 2.68 Å in chains A and B, respectively), and can 323 
thus also be considered to bridge the two metal ions. In consequence both Rm3 metal ions are 324 
five co-ordinated. 325 
Five co-ordinate metal ion systems can be described using the structural parameter τ (τ = (β - 326 
α)/60) to discriminate between trigonal (τ = 1) and square (τ = 0) pyramidal geometries (55). For 327 
the Rm3 Zn1 site the two angles α and β that represent distortion from square to trigonal 328 
bipyramidal co-ordination can be defined as His116 – Zn1 – His196 (103.5º) and Wat2 – Zn1 – 329 
His118 (167.4º), respectively (56), yielding a value for τ of 1.07 and indicating that co-330 
ordination is best described as trigonal bipyramidal. For the Zn2 site α and β are defined as Wat1 331 
– Zn2 – His263 (127.4º) and Wat2 – Zn2 – Asp120 (155.9º), respectively (57), giving τ = 0.475 332 
and co-ordination geometry as intermediate between trigonal bi- and square pyramidal. In chain 333 
B Wat2 is less well defined by the experimental electron density but occupies a similar position, 334 
with values for τ of 0.97 for the Zn1, and 0.41 for the Zn2, sites. Thus zinc co-ordination is 335 
similar in both Rm3 molecules. 336 
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 337 
Comparison with Other B3 MBL Structures 338 
PDBeFold (58) was used to generate superpositions of chain B of Rm3 with five other B3 MBLs 339 
of known crystal structure: L1 (pdb 1SML (59), RMSD 1.47 Å over 240 Cα atoms), FEZ-1 (pdb 340 
1K07 (60). RMSD 1.65 Å over 254 Cα atoms), BJP-1 (pdb 3LVZ (53), RMSD 1.73 Å over 251 341 
Cα atoms), AIM-1 (pdb 4AWY (61), RMSD 1.04 Å over 247 Cα atoms) and SMB-1 (pdb 3VPE 342 
(57), RMSD 0.87 Å over 245 Cα atoms). Thus, the Rm3 structure most closely resembles those 343 
of AIM-1 and SMB-1, consistent with the closer sequence relationship to these enzymes than to 344 
other structurally characterized B3 MBLs. Superposition of the B3 MBL structures (Figure 5) 345 
identifies three regions where there is variation between the various structures - the extreme N-346 
terminus, the loop connecting helix α4 and strand β7 (sometimes termed loop1) and that 347 
connecting strand β11 and helix α5 (loop2 (57)). Together these three regions substantially 348 
define the active site groove in B3 MBLs. Notably, the N-terminal region of Rm3 is poorly 349 
defined in the crystal structure, with no electron density evident for the proline-rich sequence 350 
(QTPAPATPP) that forms the N-terminus of the processed polypeptide after cleavage of the 351 
signal peptide. However, unlike the AIM-1 and SMB-1 structures, where a turn preceding the 352 
conserved Trp41 forces relatively short N-termini away from the active site, in Rm3 Trp41 is 353 
part of an α-helix (α1, Figure 3) that defines one wall of a deeper active site groove (Figure 5). 354 
Thus, in this regard Rm3 more closely resembles BJP-1, where an extended helical N-terminus 355 
creates an active site that is much narrower than those of other B3 MBLs of known structure. 356 
Loop1 (residues 150 – 164) of B3 MBLs also contributes substantially to the active site 357 
architecture. Hydrophobic residues (Phe156 and Ile162) in loop1 of L1 were proposed to 358 
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participate in binding of substrate (59), but subsequent directed mutagenesis investigations of L1 359 
(62) and FEZ-1 (63) did not identify these individual positions as essential to activity. However, 360 
rapid kinetic experiments (64) demonstrate that this loop can adjust its position during turnover 361 
of β-lactams by the L1 enzyme, indicating that the structure as a whole may have some 362 
mechanistic role. In addition, both AIM-1 and SMB-1 feature a Gln at position 157, where 363 
models of bound cephalosporin substrates suggest that it may interact with the carboxylate group 364 
at C7/C8 formed on hydrolysis of the β-lactam amide (57, 61). In Rm3 Gln157 is present, as part 365 
of a DPQ motif that is also found in SMB-1, AIM-1 and THIN-B, and the organization of loop1 366 
closely resembles that found in AIM-1 and SMB-1 (Figure 5). By way of contrast, loop1 in the 367 
L1, FEZ-1 and BJP-1 structures adopts a more “open” conformation than is the case here. 368 
Loop2 (residues 224 - 230) is the third region of variability between B3 MBL structures. In 369 
common with AIM-1 and SMB-1, loop2 of Rm3 is longer by two residues than its equivalent in 370 
other B3 enzymes, with the apex of this loop extending away from the active site. In L1 and 371 
FEZ-1, residues such as Asn225 (FEZ-1) and Tyr228 (both enzymes) on loop2 are proposed to 372 
contribute to β-lactam hydrolysis through interaction with the C7/C8 carboxylate group of 373 
hydrolyzed species (see above) (59, 60, 62). Consistent with the presence of Gln157 on loop1 374 
(see above) which could act as a functional replacement for these residues, the equivalent 375 
positions of Rm3 loop2 are occupied by amino acids (Val and Pro) that are unable to replicate 376 
these proposed interactions, and the conformation of loop2 is also incompatible with a 377 
contribution to β-lactam binding and/or hydrolysis. Loop2 of BJP-1 also differs from the 378 
equivalent regions of L1 and FEZ-1, but in this case it is positioned in a more “closed” 379 
conformation nearer to the zinc center. Taken together, these comparisons indicate that, in both 380 
the overall fold, and the specific architecture of variable regions (loops 1 and 2) adjacent to the 381 
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active site, the Rm3 structure more closely resembles that of the mobile B3 enzymes AIM-1 and 382 
SMB-1 than it does the chromosomal B3 MBLs L1, FEZ-1 and BJP-1. 383 
In contrast to these clear differences in overall structure between different B3 MBLs, comparison 384 
of the respective active sites indicates that the principal features of the Rm3 metal center are 385 
common between all structurally characterized B3 MBLs. Specifically, all B3 MBLs of known 386 
structure feature a binuclear zinc center with a five co-ordinate ion in the Zn2 site and geometry 387 
intermediate between trigonal bi- and square pyramidal, and (for structures that do not contain 388 
bound ligands) the zinc – zinc distance (3.46 Å and 3.51 Å in Rm3 chains A and B, respectively 389 
(see above)) varies between 3.40 and 3.58 Å (for structures determined at resolutions between 390 
1.40 Å and 1.80 Å, compared to a resolution of 1.75 Å for the structure of Rm3 presented here). 391 
With respect to other B3 enzymes, the main difference in the Rm3 active site is the positioning 392 
of the Wat2 water molecule (Figure 4b, c), which is notably closer to both Zn1 (distances 2.57 Å 393 
and 2.68 Å in Rm3 chains A and B, respectively) and Wat1 (2.33 Å and 1.96 Å) than is the case 394 
in e.g L1 (Wat2 – Zn1 and Wat2 – Wat1 distances 2.80 Å and 3.04 Å for pdb 1SML). 395 
 396 
Implications of Rm3 Structure for Activity 397 
Despite much effort, the precise mode of binding of β-lactams to the active site of B3 MBLs 398 
remains incompletely understood. In fact only one crystal structure has so far been determined 399 
for a B3 MBL complexed with antibiotic, that of L1 bound to the hydrolysis product of the 400 
oxacephem moxalactam (65); docking and quantum mechanics/molecular mechanics (QM/MM) 401 
approaches have been used to investigate interactions of AIM-1 with hydrolyzed cefoxitin (61). 402 
We therefore used superposition of the Rm3 and L1:moxalactam structures to consider possible 403 
Characterization of Rm3 Metallo-β-Lactamase 
20 
 
interactions of hydrolyzed moxalactam with Rm3 (Figure 6a, b) in an effort to investigate 404 
determinants of β-lactamase activity, and the basis for the high KM values that are observed for 405 
β-lactam hydrolysis by Rm3. 406 
Consistent with the ability of Rm3 to hydrolyze most classes of β-lactam, these comparisons 407 
imply that the enzyme can replicate many of the interactions with substrates made by L1 or 408 
AIM-1. In addition to interactions involving the two metal ions (Zn1 with the C7/C8 409 
carbonyl/carboxylate of the β-lactam amide, and Zn2 with the C3/C4 carboxylate of the second 410 
ring), the Rm3 active site contains conserved residues at positions previously implicated in β-411 
lactam binding. In particular, Ser221, a residue that is highly conserved in B3 MBLs, and 412 
Asn223 (Ser or Thr in most other B3 enzymes) are well positioned to contact the C3/C4 413 
carboxylate of bound β-lactam. Notably, in the Rm3 crystal structure the anticipated positions 414 
adopted by the β-lactam carboxylate oxygen atoms are occupied by Wat2 and by a second water 415 
molecule (Wat3) positioned between the Ser221 and Asn223 side chains. As noted earlier, and as 416 
has been proposed for AIM-1 (61) and SMB-1 (57), the Gln157 side chain is positioned to 417 
contact the C7/C8 carboxylate generated by β-lactam hydrolysis. Furthermore, the conserved 418 
Trp41 side chain is able to make hydrophobic interactions with the β-lactam core. Rm3 is thus 419 
able to make productive interactions with the core components common across the different 420 
classes of β-lactam. 421 
Given this apparent availability of productive modes of substrate binding, we then considered 422 
why Rm3 hydrolyzes β-lactams with relatively low efficiency. Inspection of molecular surfaces 423 
in the vicinity of the active site (Figure 6c, d) indicates that, compared to other B3 enzymes in 424 
which the active site sits in a relatively shallow groove, the Rm3 active site is positioned at the 425 
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bottom of a much deeper channel that runs across one side of the structure. Notably, the extended 426 
N-terminus forms one wall of this cleft in the region that would be expected to form the binding 427 
site for the C6/C7 (R1) substituent of β-lactams, either requiring substrates to adopt specific 428 
conformations on binding to avoid steric clashes, or necessitating significant conformational 429 
changes of the enzyme to render the active site more accessible to β-lactams, particularly those 430 
such as later generation cephalosporins (e.g. ceftazidime) with bulky C7 substituents. 431 
Interestingly, for the B3 MBL BJP-1, where in the unliganded enzyme the active site is occluded 432 
by the extended N-terminal α-helix, the crystal structure of a complex with a 4-433 
nitrobenzenesulfonamide inhibitor showed that inhibitor binding involved displacement of this 434 
entire helix from its position in the native structure in order to make the active site accessible 435 
(53). We thus propose that the high KM values for Rm3-catalyzed hydrolysis of β-lactams arise 436 
in large part from the steric constraints upon substrate binding that are imposed by the extended 437 
N-terminus. It is possible that the additional proline-rich N-terminal sequence, comprising a 438 
further 10 amino acids that could not be modeled in our final crystal structure, could impose 439 
further restrictions upon substrate binding. 440 
 441 
Concluding Remarks 442 
The increasing availability of sequence information from genomic and metagenomics projects 443 
has begun to establish the extent to which antibiotic resistance genes are distributed in the wider 444 
environment. It is now clear that MBLs, and the B3 subclass in particular, are frequently present 445 
on the chromosomes of environmental organisms that include, but are not limited to, opportunist 446 
human pathogens such as S. maltophilia or E. meningosepticum. Accumulating evidence shows 447 
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that the antibiotic era has been characterized by repeated instances of the mobilization of 448 
resistance determinants from environmental species, such as Kluyvera or Shewanella spp., into 449 
clinically significant pathogens, and their subsequent global dissemination on multiresistance 450 
plasmids. It is also becoming apparent that exposure to detergents and biocides, as well as 451 
antibiotics, may also be implicated in the mobilization of resistance genes, and co-selection of 452 
multiresistance elements. In this work we describe the properties of the product of a novel 453 
resistance gene, blaRm3, that was identified from an environment with high levels of biocide 454 
exposure. 455 
blaRm3 encodes a B3 MBL that is active against most β-lactam classes in vitro and is able to 456 
reduce the cephalosporin susceptibility of recombinant E. coli, thus replicating characteristics of 457 
enzymes of clinical importance. Sequence-based phylogeny indicates that Rm3 is representative 458 
of a distinct clade of B3 MBLs that differs from the L1 and FEZ-1/GOB groups (Figure 2). It is 459 
likely that, given their occurrence in environmental samples from sites that differ greatly in their 460 
geographical location and level of human impact, these enzymes have a wide distribution in the 461 
environment. With increasing use of broad-spectrum β-lactams, and the associated increase in 462 
selection pressure, there is thus considerable potential for future mobilization of MBLs of this 463 
type into the clinic. The structure of Rm3 demonstrates an overall resemblance to the mobilized 464 
AIM-1 and SMB-1 enzymes, and provides a basis both for the β-lactamase activity of Rm3 and 465 
the limited efficiency with which it hydrolyzes most substrates. However, the architecture of the 466 
active site that is created by the extended N-terminus distinguishes Rm3 from other B3 MBLs 467 
that have been studied so far, suggesting both that (as has been suggested for other B3 MBLs 468 
(50)) β-lactams may not necessarily be the natural substrates for these enzymes, and that there is 469 
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capacity for β-lactamase activity to be improved by mutation. Future experiments will 470 
investigate these possibilities.   471 
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Table 1. Effect of RM3 Expression on β-lactam MICs (μg / ml) for Recombinant 700 
Escherichia coli EC100. 701 
 AMP AMX CAR TMC ATM CTX CAZ IPM 
pCF430a 8 8 32 16 0.25 0.25 0.5 0.5 
pCF430:RM3b 16 8 32 32 0.5 0.25 8 1 
 702 
a MIC values of empty pCF430 in Escherichia coli EC100. 703 
b MIC values for pCF430 carrying 8 kb RM3 metagenomic fragment  704 
AMP = ampicillin, AMX = amoxicillin, CAR = carbenicillin, TMC = temocillin, ATM = 705 
aztreonam, CTX = Cefotaxime, CAZ = Ceftazidime, IPM = imipenem. 706 
 707 
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Table 2. Kinetic parameters for Hydrolysis of Selected β-Lactams by Rm3 and Selected B3 MBLs. 708 
 Rm3 L1 FEZ-1 d BJP-1 e AIM-1 f SMB-1 g 
β-lactam KM a kcat b kcat/KM c KM a kcat b kcat/KM c KM a kcat b kcat/KM c KM a kcat b kcat/KM c KM a kcat b kcat/KM c KM a kcat b kcat/KM c 
Penicillin G ND ND 4.1 x  
104 
75 
±10* 
410 
±20 
5.5 x 106 590 ±70 70 
±5 
1.1 x 105 130 18 1.3 x 105 31 778 2.6 x 107 ND ND ND 
Ampicillin 1600 
±260 
33.6 
±3 
2.1 x  
104 
300 
±15 
580 
±20 
1.9 x 106 >5000 >5.5 1.1 x 104 670 13 1.9 x 104 41 594 1.4 x 106 102 247 2.4 x  
106 
Cefoxitin ND ND 1.5 x  
104 
3.3 
±0.4* 
2.2 
±0.1 
6.7 x 105 11 
±1 
3 
±0.5 
2.7 x 105 140 10 7.1 x 104 26 145 5.7 x 106 26 39 1.5 x  
106 
Ceftazidime ND ND 2.1 x  
104 
145 
±13** 
27 
±3 
2.0 x 105 >1000 >4 4.0 x 103 >700 >3 4.3 x 103 148 7 4.9 x 104 57 4.4 7.7 x  
104 
Cefotaxime ND ND 7.1 x  
104 
160 
±20* 
140 
±9 
8.8 x 105 70 
±8 
165 
±15 
2.4 x 106 300 41 1.4 x 105 49 609 1.2 x 107 35 31 8.9 x  
105 
Meropenem 232 
± 9 
8.9 
±0.2 
3.8 x  
104 
13 
*** 
77 5.9 x 106 85 
±3 
45 
±2 
5.0 x 105 190 156 8.3 x 105 163 1000 6.8 x 106 144 604 4.2 x  
106 
Imipenem ND ND 1.0 x  
104 
48 
±8** 
384 
±6 
8 x  
106 
>1000 >200 2.0 x 105 260 15 6.0 x 104 97 1700 1.7 x 107 133 518 3.9 x  
106 
Aztreonam NH ND ND ND ND ND >1000 <10-2 <10 NH ND ND NH ND ND NH ND ND 
a μM b s-1 c M-1 s-1 709 
Kinetic data for L1 are from (66)*, (67)**, (68)***. 710 
Kinetic data for other enzymes are from FEZ-1 (69), BJP-1 (26), AIM-1 (14) and SMB-1 (15).  711 
 712 
 713 
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Table 3. Crystallographic Data Collection and Refinement Statistics 714 
Data Collection  
Beamline DLS (I04) 
Wavelength (Å) 0.9795 
Space Group P21 
Cell Dimensions  
a, b, c (Å) 45.88, 74.45, 77.46 
α, β, γ 90, 99.48, 90 
Molecules/asymmetric unit 2 
Resolution (Å) 53.32 - 1.75 (1.78 – 1.75)a 
No. of unique reflections 50630 (2761)a 
Redundancy 2.4 (2.3)a 
Rmerge 0.055 (0.363)a 
CC1/2 0.997 (0.821)a 
I/σ 9.1 (2.1)a 
Completeness (%) 97.6 (97.2)a 
Refinement  
Resolution (Å) 53.32 - 1.75 (1.78 – 1.75)a 
No. of reflections 50593 (2780)a 
Rwork/Rfreeb 20.28 / 22.94 (31.15 / 32.18)a
No. Protein atoms 2022c / 2029d 
No. Zinc ions 7 
No. Water molecules 302 
B factors (protein) 25.58c / 26.65d 
B-factor (zinc) 19.38 
B-factor (water) 29.25 
Bond length rmsd (Å) 0.007 
Bond angle rmsd (°) 1.09 
aHighest resolution shell statistics are shown in parentheses. 715 
bRfree was calculated with 5% of reflections omitted from refinement 716 
cchain A 717 
dchain B  718 
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Figure 1: Sequence Alignment of SubClass B3 Metallo-β-Lactamases. Alignment of selected 719 
subclass B3 MBLs. Sequences were aligned using ClustalOmega (70) invariant residues are 720 
highlighted with a red background, conservative substitutions are in red text. Residue numbering 721 
is according to the BBL standard numbering scheme (52); discontinuities (e.g. between residues 722 
5- 70 , 80 – 90 and 150 – 170) are due to omission from the Figure of other MBL subclasses. 723 
Secondary structure assignments (DSSP; (71)) are from Rm3 structure (this work). Zinc binding 724 
residues are indicated by red triangles. Cysteine pairs 208 and 213, and 256 and 290 are labeled 725 
1 and 2, respectively. Positions of key Rm3 residues and of Rm3 loops 1 and 2 are labeled below 726 
the alignment. This Figure was prepared using EsPript (72). 727 
 728 
 729 
  730 
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Figure 2: Phylogenetic Tree of Selected Subclass B3 Metallo-β-Lactamases. Sequences were 731 
aligned using ClustalOmega (70) and the phylogenetic tree was visualized using the Drawgram 732 
3.67 component of the PHYLIP package (73). 733 
 734 
 735 
  736 
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Figure 3: Overall Structure of Rm3. Stereo view of Rm3, with protein backbone color-ramped 737 
from blue (N-) to red (C-terminus). Active site residues and disulfide bonds are rendered as 738 
sticks (carbon atoms in green, other atom colors as standard). Zinc ions (gray) and water 739 
molecules (red) are shown as spheres. This Figure was generated using Pymol (www.pymol.org). 740 
 741 
 742 
  743 
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Figure 4: Rm3 Active Site. A. Stereoview; carbon atoms are colored green, zinc ions gray, 744 
water molecules red, other colors as standard. Electron density map is 2|Fo| - |Fc|.φcalc, contoured 745 
at 1.5 σ. B. Active site of Rm3 showing position of Wat2 relative to Zn1 (distance in black) and 746 
Wat1 (distance in white). C. Active site of L1 (pdb 1SML, (59)) showing position of Wat2 747 
relative to Zn1 and Wat1. This Figure was generated using Pymol. 748 
 749 
 750 
  751 
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Figure 5. Comparison of Rm3 with Other B3 MBLs. Superposition of Rm3 structure upon 752 
those of other B3 MBLs. A. Overall fold of Rm3 (chain A; color-ramped from N- (blue) to C- 753 
(red) terminus. B. SMB-1 (pdb 3VPE (57)). C. L1 (pdb 1SML (59)). D. BJP-1 (pdb 3LVZ (53)). 754 
Residues discussed in the text are rendered as sticks. This Figure was generated using Pymol. 755 
 756 
 757 
758 
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Figure 6: Proposed Interactions of Rm3 with Substrates. A. Crystal structure of L1 bound to 759 
hydrolyzed moxalactam (pdb 2AIO; (65)). B. Superposition of hydrolyzed moxalactam from pdb 760 
2AI0 on structure of Rm3 (this work). Note that superposition places the moxalactam C4 761 
carboxylate over Wat2 and Wat3, N5 and the C4 carboxylate in proximity to Zn2 and the C8 762 
carboxylate close to Zn1. C. and D. space-filling representations of the L1 complex (pdb 2AIO) 763 
and Rm3 structure (this work) with bound moxalactam superposed in stick form. The extended 764 
N-terminus of Rm3 (residues 32 - 43) is highlighted in pale green. This Figure was generated 765 
using Pymol. 766 
 767 
 768 
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